Bide Pharmatech Co., Ltd. (SHA:688073)
China · Delayed Price · Currency is CNY 76.60
+2.32 (3.12%)
At close: Sep 30, 2026
Bide Pharmatech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6,599 | 5,260 | 4,342 | 5,044 | 5,333 | - | |
Market Cap Growth | 0.77% | 21.13% | -13.91% | -5.42% | - | - |
Enterprise Value | 5,714 | 4,347 | 3,274 | 3,905 | 3,860 | - |
Last Close Price | 76.60 | 59.54 | 46.99 | 51.49 | 53.79 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 36.87 | 34.66 | 36.98 | 46.03 | 36.53 | - |
Forward PE | - | 27.56 | 31.74 | 22.50 | 30.12 | - |
PS Ratio | 4.79 | 3.97 | 3.94 | 4.62 | 6.40 | - |
PB Ratio | 3.20 | 2.57 | 2.14 | 2.41 | 2.57 | - |
P/TBV Ratio | 3.22 | 2.59 | 2.15 | 2.42 | 2.57 | - |
P/FCF Ratio | 80.95 | 1301.79 | 62.06 | - | - | - |
P/OCF Ratio | 63.55 | 185.69 | 27.43 | - | 178.53 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.14 | 3.28 | 2.97 | 3.58 | 4.63 | - |
EV/EBITDA Ratio | 21.57 | 21.53 | 26.38 | 35.88 | 25.71 | - |
EV/EBIT Ratio | 24.27 | 23.16 | 28.97 | 39.33 | 26.74 | - |
EV/FCF Ratio | 70.08 | 1075.81 | 46.79 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.07 | 0.07 | 0.04 | 0.03 | 0.02 | 0.04 |
Debt / EBITDA Ratio | 0.52 | 0.65 | 0.58 | 0.45 | 0.25 | 0.23 |
Debt / FCF Ratio | 1.68 | 34.92 | 1.18 | - | - | - |
Net Debt / Equity Ratio | -0.43 | -0.44 | -0.54 | -0.58 | -0.71 | -0.26 |
Net Debt / EBITDA Ratio | -3.54 | -4.46 | -8.85 | -11.18 | -9.78 | -1.49 |
Net Debt / FCF Ratio | -10.86 | -222.86 | -15.70 | 10.27 | 172.02 | 1.76 |
Asset Turnover | 0.55 | 0.54 | 0.46 | 0.46 | 0.51 | 0.86 |
Inventory Turnover | 0.86 | 0.90 | 0.93 | 1.10 | 0.94 | 0.91 |
Quick Ratio | 4.34 | 3.86 | 4.12 | 5.54 | 6.84 | 1.31 |
Current Ratio | 7.46 | 6.74 | 6.39 | 8.22 | 9.01 | 3.28 |
Return on Equity (ROE) | 9.06% | 7.45% | 5.71% | 5.21% | 10.79% | 19.65% |
Return on Assets (ROA) | 5.86% | 4.75% | 2.92% | 2.60% | 5.53% | 9.51% |
Return on Invested Capital (ROIC) | 15.83% | 14.06% | 9.95% | 11.55% | 22.92% | 25.82% |
Return on Capital Employed (ROCE) | 10.80% | 8.60% | 5.50% | 4.60% | 6.80% | 16.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.75% | 2.89% | 2.70% | 2.17% | 2.74% | - |
FCF Yield | 1.24% | 0.08% | 1.61% | -2.35% | -0.16% | - |
Dividend Yield | 1.51% | 1.95% | 1.92% | 1.75% | 2.04% | - |
Payout Ratio | 56.35% | 52.58% | 68.03% | 91.29% | 0.06% | 0.19% |
Buyback Yield / Dilution | 0.62% | 1.40% | 1.76% | -22.83% | -10.09% | -8.03% |
Total Shareholder Return | 2.13% | 3.35% | 3.68% | -21.08% | -8.05% | -8.03% |